- Coordinator
- Bernhard-Nocht-Institut Fuer Tropenmedizin, Germany
- Runs
- 1 September 2026 to 31 August 2031
- Status
- Running
- EU funding
- €10.1m
- Total cost
- €12.4m
- Partners
- 10 organisations in 6 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101248797
What the project is doing
In the project's own words, from its summary on CORDIS.
Severe malaria is a major cause of preventable morbidity and mortality in endemic regions. 76% of all malaria deaths occur in children <5 years in SSA. While severe malaria constitutes a medical emergency, about one third of children diagnosed with severe malaria suffer from another life-threatening infection, most commonly systemic bacterial infections. Diagnostic differentiation is often not possible in resource limited settings.
Ideally, empiric treatment for both aetiologies is warranted. However, often enough either antimalarial or antibiotic therapy is administered, putting the patient at an increased risk of death. Additionally, artemisinin partial resistant Plasmodium isolates constitute an increasing therapeutic challenge for currently recommended artesunate monotherapy. Finally, a high proportion of bacterial isolates with resistance against commonly used antibiotics poses a similar therapeutic challenge.
To overcome the 1) lack of adequate initial coverage of antimalarial and antibacterial pathogens, 2) increase of artemisinin partial resistant Plasmodium, and 3)high incidence of antimicrobial drug-resistant bacterial pathogens, we develop an antibiotic-based combination therapy with fosmidomycin-artesunate-clindamycin (FACT) for the simultaneous treatment of severe malaria and bacterial bloodstream infections. FACT includes parenteral artesunate, the currently recommended treatment of severe malaria, coverage of gram-positive and anaerobic bacteria by clindamycin and gram-negative bacteria by fosmidomycin.
Clindamycin and fosmidomycin also exert proven synergistic antimalarial activity even in artemisinin resistant isolates. Matching pharmacokinetic parameters and independent modes of action provide further protection against selection for antimalarial drug resistance. Based on previous clinical trials, this project targets the late clinical development of FACT in a Phase II and Phase III clinical trial for subsequent implementation in health services.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Bernhard-Nocht-Institut Fuer Tropenmedizin | Hamburg | Germany | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Fondation Congolaise Pour La Recherche Medicale | Brazzaville | CG | Participant |
| DMG Deutsche Malaria GmbH | Hamburg | Germany | Associatedpartner |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Eurice European Research and Project Office GmbH | St Ingbert | Germany | Participant |
| University of Hamburg | Hamburg | Germany | Participant |
| Addis Ababa University | Addis Ababa | ET | Participant |
| Centre de Recherches Medicales de Lambaréné | Lambaréné | GA | Participant |
| Kwame Nkrumah University of Science and Technology Kumasi | Kumasi | Ghana | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI